PH12013500316A1 - Treatment for neoplastic diseases - Google Patents
Treatment for neoplastic diseasesInfo
- Publication number
- PH12013500316A1 PH12013500316A1 PH1/2013/500316A PH12013500316A PH12013500316A1 PH 12013500316 A1 PH12013500316 A1 PH 12013500316A1 PH 12013500316 A PH12013500316 A PH 12013500316A PH 12013500316 A1 PH12013500316 A1 PH 12013500316A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- neoplastic diseases
- mab
- administration
- useful
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001613 neoplastic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609710P | 2010-08-23 | 2010-08-23 | |
| US40675910P | 2010-10-26 | 2010-10-26 | |
| US41118310P | 2010-11-08 | 2010-11-08 | |
| US201161480635P | 2011-04-29 | 2011-04-29 | |
| PCT/US2011/048747 WO2012027324A2 (en) | 2010-08-23 | 2011-08-23 | Treatment for neoplastic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12013500316A1 true PH12013500316A1 (en) | 2016-09-02 |
Family
ID=45594256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2013/500316A PH12013500316A1 (en) | 2010-08-23 | 2011-08-23 | Treatment for neoplastic diseases |
| PH12016500578A PH12016500578B1 (en) | 2010-08-23 | 2016-03-30 | Treatment for neoplastic diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12016500578A PH12016500578B1 (en) | 2010-08-23 | 2016-03-30 | Treatment for neoplastic diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10294296B2 (enExample) |
| EP (3) | EP2608808B1 (enExample) |
| JP (5) | JP6241932B2 (enExample) |
| KR (7) | KR20210128021A (enExample) |
| CN (3) | CN103153340A (enExample) |
| AU (1) | AU2011293554B9 (enExample) |
| DK (1) | DK2608808T3 (enExample) |
| ES (2) | ES2622482T3 (enExample) |
| IL (2) | IL262856B (enExample) |
| MX (2) | MX388939B (enExample) |
| NZ (1) | NZ607472A (enExample) |
| PH (2) | PH12013500316A1 (enExample) |
| PT (1) | PT2608808T (enExample) |
| RU (2) | RU2679119C2 (enExample) |
| SG (1) | SG187853A1 (enExample) |
| WO (1) | WO2012027324A2 (enExample) |
| ZA (1) | ZA201301420B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130098279A (ko) | 2010-06-18 | 2013-09-04 | 엑스바이오테크, 인크. | 관절염 치료 |
| KR20210128021A (ko) | 2010-08-23 | 2021-10-25 | 얀센 바이오테크 인코포레이티드 | 종양성 질병들에 대한 치료 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| CN103906536A (zh) | 2011-09-23 | 2014-07-02 | 埃克斯生物科技公司 | 恶病质治疗 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| US20170260285A1 (en) * | 2014-11-24 | 2017-09-14 | University Of Iowa Research Foundation | Methods for treating cancer |
| AU2018220862A1 (en) | 2017-02-16 | 2019-08-29 | Janssen Biotech, Inc. | Treatment of hidradenitis suppurativa |
| US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4965198A (en) | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US5034316A (en) | 1987-03-30 | 1991-07-23 | The Regents Of The University Of California | In vitro human monoclonal IgG rheumatoid factor autoantibody |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0465513A1 (en) | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| US5407431A (en) | 1989-07-11 | 1995-04-18 | Med-Design Inc. | Intravenous catheter insertion device with retractable needle |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| ES2140469T3 (es) | 1992-10-14 | 2000-03-01 | Nycomed Imaging As | Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes. |
| DE122009000074I1 (de) | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9405021D0 (en) | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| GB9509620D0 (en) | 1995-05-12 | 1995-07-05 | Nat Blood Authority | Transepithelial transport of molecular species |
| WO1997002479A2 (en) | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| US20030040617A9 (en) | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| DE60025832T2 (de) * | 1999-08-09 | 2006-08-31 | Emd Lexigen Research Center Corp., Billerica | Mehrere zytokin-antikörper komplexen |
| DE19943790C2 (de) | 1999-09-13 | 2001-11-15 | Ericsson Telefon Ab L M | Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten |
| US6380129B1 (en) | 1999-11-02 | 2002-04-30 | Richard J. Kraemer | Enhanced materials for treatment of contamination |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US20020131954A1 (en) | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| AU2007202323C1 (en) | 2000-06-29 | 2012-04-12 | Abbvie Inc. | Dual specificity antibodies and methods of making and using |
| CA2426384A1 (en) | 2000-10-19 | 2003-04-17 | Kyowa Hakko Kogyo Co., Ltd. | Antibody inhibiting vplf activity |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US7348003B2 (en) * | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| KR101033196B1 (ko) | 2002-02-14 | 2011-05-09 | 이뮤노메딕스, 인코오포레이티드 | 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법 |
| EP1483295B1 (en) | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
| US7438910B2 (en) | 2002-09-06 | 2008-10-21 | Amgen Inc. | Therapeutic human anti-IL1-R1 monoclonal antibody |
| JP4450644B2 (ja) | 2003-03-03 | 2010-04-14 | 日本化薬株式会社 | Ａｍｆ類を有効成分とする医薬製剤 |
| US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
| NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| KR100493102B1 (ko) | 2003-06-30 | 2005-06-02 | 삼성전자주식회사 | 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US7799327B2 (en) | 2003-12-24 | 2010-09-21 | Henry John Smith | Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US8957056B2 (en) | 2004-05-25 | 2015-02-17 | Sloan-Kettering Instiute For Cancer Research | Migrastatin analogs in the treatment of cancer |
| US20050276807A1 (en) | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
| US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| KR101281501B1 (ko) * | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
| ES2346691T3 (es) | 2005-08-02 | 2010-10-19 | Xbiotech, Inc | Diagnostico, tratamiento y prevencion de trastornos vasculares usando autoanticuerpos il-1alfa. |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| JP5312028B2 (ja) | 2005-09-28 | 2013-10-09 | サイトス バイオテクノロジー アーゲー | インターロイキン−１コンジュゲート及びその使用 |
| BRPI0709977A2 (pt) | 2006-04-14 | 2011-08-02 | Novartis Ag | uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos |
| US20090191149A1 (en) | 2006-05-15 | 2009-07-30 | Xbiotech Inc. | IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS |
| US20110008282A1 (en) | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| SI2109623T1 (sl) * | 2006-05-22 | 2012-05-31 | Xbiotech Inc | Zdravljenje raka z anti il protitelesi |
| US8524865B2 (en) | 2006-05-30 | 2013-09-03 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| FR2902659A1 (fr) | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
| US8324350B2 (en) | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
| EP3632444A3 (en) | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| JP5670318B2 (ja) | 2008-05-30 | 2015-02-18 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | インターロイキン１α抗体及び有用な方法 |
| JP5976319B2 (ja) | 2008-09-12 | 2016-08-23 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 病原性単球の標的化 |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| BRPI1007371A2 (pt) * | 2009-01-29 | 2018-03-27 | Abbott Lab | proteínas de ligação a il-1 |
| FR2945396A1 (fr) * | 2009-05-07 | 2010-11-12 | St Microelectronics Grenoble 2 | Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce |
| UY32949A (es) | 2009-10-15 | 2011-02-28 | Abbott Lab | Proteínas de unión a il-1 |
| RS57543B1 (sr) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Primene i kompozicije za lečenje hidradenitis suppurativa (hs) |
| KR20130098279A (ko) | 2010-06-18 | 2013-09-04 | 엑스바이오테크, 인크. | 관절염 치료 |
| KR20210128021A (ko) | 2010-08-23 | 2021-10-25 | 얀센 바이오테크 인코포레이티드 | 종양성 질병들에 대한 치료 |
| NZ607510A (en) | 2010-09-10 | 2014-10-31 | Apexigen Inc | Anti-il-1 beta antibodies and methods of use |
| US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
| ES2697056T3 (es) | 2011-04-01 | 2019-01-21 | Xbiotech Inc | Tratamiento para patologías dermatológicas |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| JP5812669B2 (ja) | 2011-04-27 | 2015-11-17 | キヤノン株式会社 | 画像処理装置および画像処理方法およびコンピュータプログラム。 |
| CN103906536A (zh) | 2011-09-23 | 2014-07-02 | 埃克斯生物科技公司 | 恶病质治疗 |
| US20130195877A1 (en) | 2012-01-31 | 2013-08-01 | Xbiotech, Inc. | Treatment of cachexia by targeting interleukin-1 beta |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| AU2013327498B2 (en) | 2012-10-04 | 2018-06-28 | Janssen Biotech, Inc. | Treatment of psychiatric conditions |
| WO2014055544A1 (en) | 2012-10-04 | 2014-04-10 | Xbiotech, Inc. | Treating vascular disease and complications thereof |
| EP2975054A4 (en) | 2013-03-12 | 2016-11-23 | Zenyaku Kogyo Kk | ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| US20150024031A1 (en) | 2013-07-17 | 2015-01-22 | Baxter International Inc. | Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent |
| EP3154584B1 (en) | 2014-06-03 | 2021-08-04 | XBiotech Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
| AU2018220862A1 (en) | 2017-02-16 | 2019-08-29 | Janssen Biotech, Inc. | Treatment of hidradenitis suppurativa |
-
2011
- 2011-08-23 KR KR1020217032773A patent/KR20210128021A/ko not_active Ceased
- 2011-08-23 EP EP11820492.4A patent/EP2608808B1/en active Active
- 2011-08-23 KR KR1020177026757A patent/KR101910760B1/ko active Active
- 2011-08-23 US US13/215,464 patent/US10294296B2/en active Active
- 2011-08-23 KR KR1020167013067A patent/KR20160062200A/ko not_active Ceased
- 2011-08-23 JP JP2013526085A patent/JP6241932B2/ja active Active
- 2011-08-23 ES ES11820492.4T patent/ES2622482T3/es active Active
- 2011-08-23 AU AU2011293554A patent/AU2011293554B9/en active Active
- 2011-08-23 ES ES18199427T patent/ES2856723T3/es active Active
- 2011-08-23 RU RU2017112088A patent/RU2679119C2/ru active
- 2011-08-23 RU RU2013110030/15A patent/RU2013110030A/ru unknown
- 2011-08-23 CN CN2011800476614A patent/CN103153340A/zh active Pending
- 2011-08-23 DK DK11820492.4T patent/DK2608808T3/en active
- 2011-08-23 KR KR1020187029749A patent/KR102104296B1/ko active Active
- 2011-08-23 SG SG2013011242A patent/SG187853A1/en unknown
- 2011-08-23 KR KR1020247029350A patent/KR102748255B1/ko active Active
- 2011-08-23 CN CN201710452010.2A patent/CN107252484A/zh active Pending
- 2011-08-23 MX MX2016013346A patent/MX388939B/es unknown
- 2011-08-23 PT PT118204924T patent/PT2608808T/pt unknown
- 2011-08-23 CN CN201710556357.1A patent/CN107281488B/zh active Active
- 2011-08-23 WO PCT/US2011/048747 patent/WO2012027324A2/en not_active Ceased
- 2011-08-23 KR KR1020207002089A patent/KR102314003B1/ko active Active
- 2011-08-23 NZ NZ607472A patent/NZ607472A/en unknown
- 2011-08-23 MX MX2013002160A patent/MX342776B/es active IP Right Grant
- 2011-08-23 KR KR1020137007024A patent/KR20130108305A/ko not_active Ceased
- 2011-08-23 EP EP18199427.8A patent/EP3443985B1/en active Active
- 2011-08-23 EP EP16165736.6A patent/EP3075394B1/en active Active
- 2011-08-23 PH PH1/2013/500316A patent/PH12013500316A1/en unknown
-
2013
- 2013-02-25 ZA ZA2013/01420A patent/ZA201301420B/en unknown
-
2016
- 2016-03-30 PH PH12016500578A patent/PH12016500578B1/en unknown
- 2016-05-19 JP JP2016100753A patent/JP6917681B2/ja active Active
-
2018
- 2018-11-07 IL IL262856A patent/IL262856B/en active IP Right Grant
- 2018-12-20 US US16/228,060 patent/US11932688B2/en active Active
-
2019
- 2019-07-05 JP JP2019125907A patent/JP7316120B2/ja active Active
-
2020
- 2020-06-14 IL IL275350A patent/IL275350B/en unknown
-
2021
- 2021-06-09 JP JP2021096528A patent/JP2021138750A/ja active Pending
-
2023
- 2023-08-11 US US18/448,526 patent/US20230382989A1/en active Pending
-
2025
- 2025-08-08 JP JP2025133305A patent/JP2025166117A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500578B1 (en) | Treatment for neoplastic diseases | |
| NZ703481A (en) | Cd37-binding molecules and immunoconjugates thereof | |
| NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| IN2015DN00450A (enExample) | ||
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| EP2426148A4 (en) | ANTI-IL-3RA ANTIBODY FOR USE IN THE TREATMENT OF HEMATOMAS | |
| UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
| ZA201202384B (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
| IN2015KN00350A (enExample) | ||
| GB201109238D0 (en) | Antibodies | |
| PH12014500645A1 (en) | Cachexia treatment | |
| TN2009000490A1 (en) | Cancer treatment combination therapy comprising vinflunine and trastuzumab | |
| CY1121012T1 (el) | Ταπενταδολη για την προληψη της χρονιοποιησης του πονου | |
| MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
| DK2665746T3 (en) | Antibodies against the s100p protein for the treatment and diagnosis of cancer |